ABBV-859
/ AbbVie
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
August 04, 2026
A Study to Assess the Safety, Tolerability and How Single Ascending Doses of ABBV-859 Moves Through the Body of Healthy Adult Participants
(clinicaltrials.gov)
- P1 | N=64 | Recruiting | Sponsor: AbbVie | Not yet recruiting ➔ Recruiting
Enrollment open • First-in-human
July 31, 2026
A Study to Assess the Safety, Tolerability and How Single Ascending Doses of ABBV-859 Moves Through the Body of Healthy Adult Participants
(clinicaltrials.gov)
- P1 | N=64 | Not yet recruiting | Sponsor: AbbVie
First-in-human • New P1 trial
1 to 2
Of
2
Go to page
1